Document:

Exhibit 10.2

 

NEITHER THIS DEBENTURE NOR THE SECURITIES
INTO WHICH THIS DEBENTURE IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION
OF ANY STATE. THESE SECURITIES HAVE BEEN SOLD IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933,
AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO,
THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS.

 

Q
BIOMED INC.

 

Convertible
Debenture

 

Principal Amount:   $[____________]

 

Debenture Issuance Date: [_____________]

 

Debenture Number: QBIO – [7][
]

 

FOR VALUE RECEIVED,
Q BIOMED INC., a Nevada corporation (the "Company"), hereby promises to pay to the order of YA II PN, Ltd., or
its registered assigns (the "Holder") the amount set out above as the Principal Amount (as reduced pursuant to
the terms hereof pursuant to redemption, conversion or otherwise, the "Principal") when due, whether upon the
Maturity Date (as defined below), acceleration, redemption or otherwise (in each case in accordance with the terms hereof) and
to pay interest ("Interest") on any outstanding Principal at the applicable Interest Rate from the date set out
above as the Debenture Issuance Date (the "Issuance Date") until the same becomes due and payable, whether upon
an Interest Date (as defined below), the Maturity Date or acceleration, conversion, redemption or otherwise (in each case in accordance
with the terms hereof). This Convertible Debenture (including all debentures issued in exchange, transfer or replacement hereof,
this "Debenture") was issued pursuant to the Securities Purchase Agreement dated December ___, 2019 (the “Securities
Purchase Agreement”) between the Company and the Buyers listed on the Schedule of Buyers attached thereto. Certain capitalized
terms used herein are defined in Section 16.

 

(1)              
GENERAL TERMS

 

(a)               
Maturity Date. On the Maturity Date, the Company shall pay to the Holder an amount in cash representing all outstanding
Principal, accrued and unpaid Interest, and any other amounts outstanding pursuant to the terms of this Debenture. The "Maturity
Date" shall be June ___, 2021, as may be extended at the option of the Holder. Other than as specifically permitted by
this Debenture, the Company may not prepay or redeem any portion of the outstanding Principal and accrued and unpaid Interest.

 

    

     

    

 

(b)              
Interest Rate and Payment of Interest. Interest shall accrue on the outstanding Principal balance hereof at an annual
rate equal to 5.5% (“Interest Rate”). Interest shall be calculated on the basis of a 365-day year and the actual
number of days elapsed, to the extent permitted by applicable law.

 

(c)                Monthly
Payments. If, any time after [_________]
1, and from time to time thereafter, the daily VWAP is less than the Floor Price for a period of 20 consecutive
Trading Days (each such occurrence, a “Triggering Event”), then the Company shall make monthly
amortization payments beginning on the last calendar day of the month when the Triggering Event occurred. Each monthly
payment shall be in an amount equal to the sum of (i) the Principal Amount outstanding as of the date of such Triggering
Event divided by the number of such monthly payments until the Maturity Date, (ii) the Redemption Premium (as defined below)
in respect of such Principal Amount, and (iii) accrued and unpaid interest hereunder as of each payment date. Each monthly
payment obligation shall be reduced by any amounts converted since the last monthly payment. The obligation of the Company to
make monthly payments hereunder shall cease if any time after the Triggering Event the daily VWAP is greater than the Floor
Price for a period of 20 consecutive Trading Days, unless a subsequent Triggering Date occurs. The Company may, no more than
twice, obtain a thirty (30) day deferral of a monthly payment due under this Section 1(c) through the payment of a deferral
fee in the amount equal to ten percent (10%) of the principal amount of such monthly payment (each, a “Deferral
Payment”). Each Deferral Payment may be paid at the option of the Company either in cash, or by the issuance of
such number of shares as is equal to the applicable Deferral Payment divided by a price per share equal to 93% of the average
of the 4 lowest daily VWAPs during the 10 consecutive Trading Days immediately preceding the due date in respect of such
monthly payment begin deferred, provided that such shares issued will be immediately freely tradable shares in the hands of
the Holder.

 

(d)               
Redemption. The Company at its option shall have the right to redeem (“Optional Redemption”) a
portion or all amounts outstanding under this Debenture prior to the Maturity Date provided that the trading price of the Common
Stock is less than the Fixed Conversion Price. The Company shall pay an amount equal to the Principal amount being redeemed plus
the applicable Redemption Premium, and accrued Interest, (collectively referred to as the “Redemption Amount”).
In order to make a redemption pursuant to this Section, the Company shall first provide written notice to the Holder of its intention
to make a redemption (the “Redemption Notice”) setting forth the amount of Principal it desires to redeem. After
receipt of the Redemption Notice the Holder shall have 5 Business Days to elect to convert all or any portion of this Debenture,
subject to the limitations set forth herein. On the 6th Business Day after the Redemption Notice, the Company shall deliver to
the Holder the Redemption Amount with respect to the Principal amount redeemed after giving effect to conversions effected during
the 5 Business Day period.

 

(2)              
EVENTS OF DEFAULT.

 

(a)                An
“Event of Default,” wherever used herein, means any one of the following events (whatever the reason and
whether it shall be voluntary or involuntary or effected by operation of law or pursuant to any judgment, decree or order
of any court, or any order, rule or regulation of any administrative or governmental body):

 

 

1
Insert date 6 months after the Issuance Date of each Debenture.

 

    2

     

    

 

(i)               
the Company's failure to pay to the Holder any amount of Principal, Interest, or other amounts when and as due under this
Debenture or any other Transaction Document within five (5) Business Days after such payment is due;

 

(ii)             
The Company or any subsidiary of the Company shall commence, or there shall be commenced against the Company or any subsidiary
of the Company under any applicable bankruptcy or insolvency laws as now or hereafter in effect or any successor thereto, or the
Company or any subsidiary of the Company commences any other proceeding under any reorganization, arrangement, adjustment of debt,
relief of debtors, dissolution, insolvency or liquidation or similar law of any jurisdiction whether now or hereafter in effect
relating to the Company or any subsidiary of the Company or there is commenced against the Company or any subsidiary of the Company
any such bankruptcy, insolvency or other proceeding which remains undismissed for a period of 61 days; or the Company or any subsidiary
of the Company is adjudicated insolvent or bankrupt; or any order of relief or other order approving any such case or proceeding
is entered; or the Company or any subsidiary of the Company suffers any appointment of any custodian, private or court appointed
receiver or the like for it or any substantial part of its property which continues undischarged or unstayed for a period of sixty
one (61) days; or the Company or any subsidiary of the Company makes a general assignment for the benefit of creditors; or the
Company or any subsidiary of the Company shall fail to pay, or shall state that it is unable to pay, or shall be unable to pay,
its debts generally as they become due; or the Company or any subsidiary of the Company shall call a meeting of its creditors with
a view to arranging a composition, adjustment or restructuring of its debts; or the Company or any subsidiary of the Company shall
by any act or failure to act expressly indicate its consent to, approval of or acquiescence in any of the foregoing; or any corporate
or other action is taken by the Company or any subsidiary of the Company for the purpose of effecting any of the foregoing;

 

(iii)             The
Company or any subsidiary of the Company shall default in any of its obligations under any other debenture or any mortgage, credit
agreement or other facility, indenture agreement, factoring agreement or other instrument under which there may be issued, or
by which there may be secured or evidenced any indebtedness for borrowed money or money due under any long term leasing or factoring
arrangement of the Company or any subsidiary of the Company in an amount exceeding $200,000, whether such indebtedness now exists
or shall hereafter be created and such default shall result in such indebtedness becoming or being declared due and payable and
such default is not cured within five (5) Business Days;

 

(iv)            
The Common Stock shall cease to be quoted or listed for trading, fail to have a bid price or VWAP, or fail to maintain a
trading market on any Primary Market, for a period of 10 consecutive Trading Days;

 

(v)             
The Company or any subsidiary of the Company shall be a party to any Change of Control Transaction (as defined in Section
16) unless in connection with such Change of Control Transaction this Debenture is retired;

 

    3

     

    

 

(vi)            
the Company's (A) failure to cure a Conversion Failure by delivery of (I) the required number of shares of Common Stock
or (II) the Buy-In Price within five (5) Business Days after the applicable Conversion Failure or (B) notice, written or oral,
to any holder of the Debentures, including by way of public announcement, at any time, of its intention not to comply with a request
for conversion of any Debentures into shares of Common Stock that is tendered in accordance with the provisions of the Debentures,
other than pursuant to Section 4(c);

 

(vii)           
The Company shall fail for any reason to deliver the payment in cash pursuant to a Buy-In (as defined herein) within five
(5) Business Days after such payment is due;

 

(viii)          
The Company shall fail to observe or perform any other material covenant, agreement or warranty contained in, or otherwise
commit any material breach or default of any provision of this Debenture (except as may be covered by Section 2(a)(i) through 2(a)(vii)
hereof) or any Transaction Document (as defined in Section 16) which is not cured within the time prescribed.

 

(ix)             
any Event of Default (as defined in the Other Debentures) occurs with respect to any Other Debentures.

 

(b)               
During the time that any portion of this Debenture is outstanding, if any Event of Default has occurred and is continuing,
the full unpaid Principal amount of this Debenture, together with interest and other amounts owing in respect thereof, to the date
of acceleration shall become at the Holder's election, immediately due and payable in cash. Furthermore, in addition to any other
remedies, the Holder shall have the right (but not the obligation) to convert this Debenture (subject to the beneficial ownership
limitations set out in Section 3(d)) at any time after (x) an Event of Default (provided that such Event of Default is continuing)
or (y) the Maturity Date at the Conversion Price. The Holder need not provide and the Company hereby waives any presentment, demand,
protest or other notice of any kind, (other than required notice of conversion) and the Holder may immediately enforce any and
all of its rights and remedies hereunder and all other remedies available to it under applicable law. Such declaration may be rescinded
and annulled by Holder at any time prior to payment hereunder. No such rescission or annulment shall affect any subsequent Event
of Default or impair any right consequent thereon.

 

(3)              
CONVERSION OF DEBENTURE.This Debenture shall be convertible into shares of the Company's Common Stock, on the
terms and conditions set forth in this Section 3.

 

(a)                Conversion
Right. Subject to the provisions of Section 3(c), at any time or times on or after the Issuance Date, the Holder shall be
entitled to convert any portion of the outstanding and unpaid Conversion Amount (as defined below) into fully paid and
nonassessable shares of Common Stock in accordance with Section 3(b), at the Conversion Rate (as defined below). The number
of shares of Common Stock issuable upon conversion of any Conversion Amount pursuant to this Section 3(a) shall be
determined by dividing (x) such Conversion Amount by (y) the Conversion Price (the "Conversion Rate"). The
Company shall not issue any fraction of a share of Common Stock upon any conversion. All calculations under this Section (3)
shall be rounded to the nearest $0.0001. If the issuance would result in the issuance of a fraction of a share of Common
Stock, the Company shall round such fraction of a share of Common Stock up to the nearest whole share. The Company shall pay
any and all transfer, stamp and similar taxes that may be payable with respect to the issuance and delivery of Common Stock
upon conversion of any Conversion Amount.

 

    4

     

    

 

(i)              
"Conversion Amount" means the portion of the Principal and accrued Interest to be converted, redeemed or
otherwise with respect to which this determination is being made.

 

(ii)             
"Conversion Price" means, as of any Conversion Date (as defined below) or other date of determination the
lower of (i) $3.00 (the “Fixed Conversion Price”), (ii) 93% of the average of the 4 lowest daily VWAPs during
the 10 consecutive Trading Days immediately preceding the Conversion Date or other date of determination, but not lower than the
Floor Price or (iii) a price agreed to by the Company and the Holder (as applicable, the “Conversion Price”).
The Conversion Price shall be adjusted from time to time pursuant to the other terms and conditions of this Debenture.

 

(b)               
Mechanics of Conversion.

 

(i)              
Optional Conversion. To convert any Conversion Amount into shares of Common Stock on any date (a "Conversion
Date"), the Holder shall (A) transmit by facsimile (or otherwise deliver), for receipt on or prior to 11:59 p.m., New
York Time, on such date, a copy of an executed notice of conversion in the form attached hereto as Exhibit I (the "Conversion
Notice") to the Company and (B) if required by Section 3(b)(iv), surrender this Debenture to a nationally recognized overnight
delivery service for delivery to the Company (or an indemnification undertaking reasonably satisfactory to the Company with respect
to this Debenture in the case of its loss, theft or destruction). On or before the third Business Day following the date of receipt
of a Conversion Notice (the "Share Delivery Date"), the Company shall (X) if legends are not required to be placed
on certificates of Common Stock and provided that the Transfer Agent is participating in the Depository Trust Company's ("DTC")
Fast Automated Securities Transfer Program, credit such aggregate number of shares of Common Stock to which the Holder shall be
entitled to the Holder's or its designee's balance account with DTC through its Deposit Withdrawal Agent Commission system or (Y)
if the Transfer Agent is not participating in the DTC Fast Automated Securities Transfer Program, issue and deliver to the address
as specified in the Conversion Notice, a certificate, registered in the name of the Holder or its designee, for the number of shares
of Common Stock to which the Holder shall be entitled which certificates shall not bear any restrictive legends unless required
pursuant to rules and regulations of the Commission. If this Debenture is physically surrendered for conversion and the outstanding
Principal of this Debenture is greater than the Principal portion of the Conversion Amount being converted, then the Company shall
as soon as practicable and in no event later than three (3) Business Days after receipt of this Debenture and at its own expense,
issue and deliver to the holder a new Debenture representing the outstanding Principal not converted. The Person or Persons entitled
to receive the shares of Common Stock issuable upon a conversion of this Debenture shall be treated for all purposes as the record
holder or holders of such shares of Common Stock upon the transmission of a Conversion Notice.

 

    5

     

    

 

(ii)              
Company's Failure to Timely Convert. If within three (3) Trading Days after the Company's receipt of the facsimile copy
of a Conversion Notice the Company shall fail to issue and deliver a certificate to the Holder or credit the Holder's balance
account with DTC for the number of shares of Common Stock to which the Holder is entitled upon such holder's conversion of
any Conversion Amount (a "Conversion Failure"), and if on or after such Trading Day the Holder purchases (in
an open market transaction or otherwise) Common Stock to deliver in satisfaction of a sale by the Holder of Common Stock
issuable upon such conversion that the Holder anticipated receiving from the Company (a "Buy-In"), then the
Company shall, within three (3) Business Days after the Holder's request and in the Holder's discretion, either (i) pay cash
to the Holder in an amount equal to the Holder's total purchase price (including brokerage commissions and other out of
pocket expenses, if any) for the shares of Common Stock so purchased (the "Buy-In Price"), at
which point the Company's obligation to deliver such certificate (and to issue such Common Stock) shall terminate, or (ii)
promptly honor its obligation to deliver to the Holder a certificate or certificates representing such Common Stock and pay
cash to the Holder in an amount equal to the excess (if any) of the Buy-In Price over the product of (A) such number of
shares of Common Stock, times (B) the Closing Bid Price on the Conversion Date.

 

(iii)             
Book-Entry. Notwithstanding anything to the contrary set forth herein, upon conversion of any portion of this Debenture
in accordance with the terms hereof, the Holder shall not be required to physically surrender this Debenture to the Company unless
(A) the full Conversion Amount represented by this Debenture is being converted or (B) the Holder has provided the Company with
prior written notice (which notice may be included in a Conversion Notice) requesting reissuance of this Debenture upon physical
surrender of this Debenture. The Holder and the Company shall maintain records showing the Principal and Interest converted and
the dates of such conversions or shall use such other method, reasonably satisfactory to the Holder and the Company, so as not
to require physical surrender of this Debenture upon conversion.

 

(c)               
Limitations on Conversions.

 

(i)                Beneficial
Ownership. The Holder shall not have the right to convert any portion of this Debenture or otherwise receive shares of
Common Stock hereunder (including pursuant to section (1)(c) or (3)(e)) to the extent that after giving effect to such
conversion or receipt of such shares, the Holder, together with any affiliate thereof, would beneficially own (as
determined in accordance with Section 13(d) of the Exchange Act and the rules promulgated thereunder) in excess of 4.99% of
the number of shares of Common Stock outstanding immediately after giving effect to such conversion or receipt of shares as
payment of interest. Since the Holder will not be obligated to report to the Company the number of shares of Common Stock it
may hold at the time of a conversion hereunder, unless the conversion at issue would result in the issuance of shares of
Common Stock in excess of 4.99% of the then outstanding shares of Common Stock without regard to any other shares which may
be beneficially owned by the Holder or an affiliate thereof, the Holder shall have the authority and obligation to determine
whether the restriction contained in this Section will limit any particular conversion hereunder and to the extent that the
Holder determines that the limitation contained in this Section applies, the determination of which portion of the Principal
amount of this Debenture is convertible shall be the responsibility and obligation of the Holder. If the Holder has delivered
a Conversion Notice for a Principal amount of this Debenture that, without regard to any other shares that the Holder or its
affiliates may beneficially own, would result in the issuance in excess of the permitted amount hereunder, the Company shall
notify the Holder of this fact and shall honor the conversion for the maximum Principal amount permitted to be converted on
such Conversion Date in accordance with Section 3(a) and, any Principal amount tendered for conversion in excess of the
permitted amount hereunder shall remain outstanding under this Debenture. The provisions of this Section may be waived by a
Holder (but only as to itself and not to any other Holder) upon not less than 65 days prior notice to the Company. Other
Holders shall be unaffected by any such waiver.

 

    6

     

    

 

(d)               
Other Provisions.

 

(i)               
The Company shall at all times reserve and keep available out of its authorized Common Stock the full number of shares of
Common Stock issuable upon conversion of all outstanding amounts under this Debenture; and within three (3) Business Days following
the receipt by the Company of a Holder's notice that such minimum number of Underlying Shares is not so reserved, the Company shall
promptly reserve a sufficient number of shares of Common Stock to comply with such requirement.

 

(ii)              
All calculations under this Section 3 shall be rounded to the nearest $0.0001 or whole share.

 

(iii)             
The Company covenants that it will at all times reserve and keep available out of its authorized and unissued shares of
Common Stock solely for the purpose of issuance upon conversion of this Debenture and payment of interest on this Debenture, each
as herein provided, free from preemptive rights or any other actual contingent purchase rights of persons other than the Holder,
not less than such number of shares of the Common Stock as shall be issuable (taking into account the adjustments and restrictions
set forth herein) upon the conversion of the outstanding Principal amount of this Debenture and payment of interest hereunder.
The Company covenants that all shares of Common Stock that shall be so issuable shall, upon issue, be duly and validly authorized,
issued and fully paid, nonassessable and, if the Underlying Shares Registration Statement has been declared effective under the
Securities Act, registered for public sale in accordance with such Underlying Shares Registration Statement.

 

(iv)             
Nothing herein shall limit a Holder's right to pursue actual damages or declare an Event of Default pursuant to Section
2 herein for the Company’s failure to deliver certificates representing shares of Common Stock upon conversion within the
period specified herein and such Holder shall have the right to pursue all remedies available to it at law or in equity including,
without limitation, a decree of specific performance and/or injunctive relief, in each case without the need to post a bond or
provide other security. The exercise of any such rights shall not prohibit the Holder from seeking to enforce damages pursuant
to any other Section hereof or under applicable law.

 

(4)              
Adjustments to Conversion Price

 

(a)                Adjustment
of Conversion Price upon Subdivision or Combination of Common Stock. If the Company, at any time while this Debenture is
outstanding, shall (a) pay a stock dividend or otherwise make a distribution or distributions on shares of its Common
Stock or any other equity or equity equivalent securities payable in shares of Common Stock, (b) subdivide outstanding shares
of Common Stock into a larger number of shares, (c) combine (including by way of reverse stock split) outstanding shares of
Common Stock into a smaller number of shares, or (d) issue by reclassification of shares of the Common Stock any shares
of capital stock of the Company, then each of the Fixed Conversion Price and the Floor Price shall be multiplied by a
fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding
before such event and of which the denominator shall be the number of shares of Common Stock outstanding after such event.
Any adjustment made pursuant to this Section shall become effective immediately after the record date for the determination
of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective
date in the case of a subdivision, combination or re-classification.

 

    7

     

    

 

(b)               
Other Events. If any event occurs of the type contemplated by the provisions of this Section (4) but not expressly
provided for by such provisions (including, without limitation, the granting of stock appreciation rights, phantom stock rights
or other rights with equity features, or issuing Convertible Securities with a variable conversion formula that is more favorable
than this Debenture), then the Company's Board of Directors will make an appropriate adjustment in the Conversion Price so as to
protect the rights of the Holder under this Debenture; provided that no such adjustment will increase the Conversion Price as otherwise
determined pursuant to this Section 5.

 

(c)               
Other Corporate Events. In addition to and not in substitution for any other rights hereunder, prior to the consummation
of any Fundamental Transaction pursuant to which holders of shares of Common Stock are entitled to receive securities or other
assets with respect to or in exchange for shares of Common Stock (a "Corporate Event"), the Company shall make
appropriate provision to insure that the Holder will thereafter have the right to receive upon a conversion of this Debenture,
at the Holder's option, (i) in addition to the shares of Common Stock receivable upon such conversion, such securities or other
assets to which the Holder would have been entitled with respect to such shares of Common Stock had such shares of Common Stock
been held by the Holder upon the consummation of such Corporate Event (without taking into account any limitations or restrictions
on the convertibility of this Debenture) or (ii) in lieu of the shares of Common Stock otherwise receivable upon such conversion,
such securities or other assets received by the holders of shares of Common Stock in connection with the consummation of such Corporate
Event in such amounts as the Holder would have been entitled to receive had this Debenture initially been issued with conversion
rights for the form of such consideration (as opposed to shares of Common Stock) at a conversion rate for such consideration commensurate
with the Conversion Rate. Provision made pursuant to the preceding sentence shall be in a form and substance satisfactory to the
Required Holders. The provisions of this Section shall apply similarly and equally to successive Corporate Events and shall be
applied without regard to any limitations on the conversion or redemption of this Debenture.

 

(d)               
Whenever the Conversion Price is adjusted pursuant to Section 4 hereof, the Company shall promptly mail to the Holder a
notice setting forth the Conversion Price after such adjustment and setting forth a brief statement of the facts requiring such
adjustment.

 

(e)                In
case of any (1) merger or consolidation of the Company or any subsidiary of the Company with or into another Person, or (2)
sale by the Company or any subsidiary of the Company of more than one-half of the assets of the Company in one or a series of
related transactions, a Holder shall have the right to (A) exercise any rights under Section 2(b), (B) convert the
aggregate amount of this Debenture then outstanding into the shares of stock and other securities, cash and property
receivable upon or deemed to be held by holders of Common Stock following such merger, consolidation or sale, and such Holder
shall be entitled upon such event or series of related events to receive such amount of securities, cash and property as the
shares of Common Stock into which such aggregate Principal amount of this Debenture could have been converted immediately
prior to such merger, consolidation or sales would have been entitled, or (C) in the case of a merger or consolidation,
require the surviving entity to issue to the Holder a convertible Debenture with a Principal amount equal to the aggregate
Principal amount of this Debenture then held by such Holder, plus all accrued and unpaid interest and other amounts owing
thereon, which such newly issued convertible Debenture shall have terms identical (including with respect to conversion) to
the terms of this Debenture, and shall be entitled to all of the rights and privileges of the Holder of this Debenture set
forth herein and the agreements pursuant to which this Debentures were issued. In the case of clause (C), the conversion
price applicable for the newly issued shares of convertible preferred stock or convertible Debentures shall be based upon the
amount of securities, cash and property that each share of Common Stock would receive in such transaction and the Conversion
Price in effect immediately prior to the effectiveness or closing date for such transaction. The terms of any such merger,
sale or consolidation shall include such terms so as to continue to give the Holder the right to receive the securities, cash
and property set forth in this Section upon any conversion or redemption following such event. This provision shall similarly
apply to successive such events.

 

    8

     

    

 

(5)              
REISSUANCE OF THIS DEBENTURE.

 

(a)                
Transfer. If this Debenture is to be transferred, the Holder shall surrender this Debenture to the Company, whereupon
the Company will forthwith issue and deliver upon the order of the Holder a new Debenture (in accordance with Section 5(d)), registered
in the name of the registered transferee or assignee, representing the outstanding Principal being transferred by the Holder (along
with any accrued and unpaid interest thereof) and, if less then the entire outstanding Principal is being transferred, a new Debenture
(in accordance with Section 5(d)) to the Holder representing the outstanding Principal not being transferred. The Holder and any
assignee, by acceptance of this Debenture, acknowledge and agree that, by reason of the provisions of Section 3(b)(iii) following
conversion or redemption of any portion of this Debenture, the outstanding Principal represented by this Debenture may be less
than the Principal stated on the face of this Debenture.

 

(b)               
Lost, Stolen or Mutilated Debenture. Upon receipt by the Company of evidence reasonably satisfactory to the Company
of the loss, theft, destruction or mutilation of this Debenture, and, in the case of loss, theft or destruction, of any indemnification
undertaking by the Holder to the Company in customary form and, in the case of mutilation, upon surrender and cancellation of this
Debenture, the Company shall execute and deliver to the Holder a new Debenture (in accordance with Section 5(d)) representing the
outstanding Principal.

 

(c)                Debenture
Exchangeable for Different Denominations. This Debenture is exchangeable, upon the surrender hereof by the Holder at the
principal office of the Company, for a new Debenture or Debentures (in accordance with Section 5(d)) representing in the
aggregate the outstanding Principal of this Debenture, and each such new Debenture will represent such portion of such
outstanding Principal as is designated by the Holder at the time of such surrender.

 

    9

     

    

 

(d)               
Issuance of New Debentures. Whenever the Company is required to issue a new Debenture pursuant to the terms of this
Debenture, such new Debenture (i) shall be of like tenor with this Debenture, (ii) shall represent, as indicated on the face of
such new Debenture, the Principal remaining outstanding (or in the case of a new Debenture being issued pursuant to Section 5(a)
or Section 5(c), the Principal designated by the Holder which, when added to the Principal represented by the other new Debentures
issued in connection with such issuance, does not exceed the Principal remaining outstanding under this Debenture immediately prior
to such issuance of new Debentures), (iii) shall have an issuance date, as indicated on the face of such new Debenture, which is
the same as the Issuance Date of this Debenture, (iv) shall have the same rights and conditions as this Debenture, and (v) shall
represent accrued and unpaid Interest from the Issuance Date.

 

(6)              
NOTICES.  Any notices, consents, waivers or other communications required or permitted to be given under the terms
hereof must be in writing and will be deemed to have been delivered: (i) upon receipt, when delivered personally; (ii) upon receipt,
when sent by email (provided confirmation of transmission is electronically generated and kept on file by the sending party); or
(iii) one (1) Trading Day after deposit with a nationally recognized overnight delivery service, in each case properly addressed
to the party to receive the same. The addresses and email for such communications shall be:

 

	If to the Company, to:	Q Biomed Inc.
	 	
        c/o Ortoli Rosenstadt LLP

        366 Madison Avenue, 3rd Floor

        New York, NY 10017

	 	Attn: William Rosenstadt
	 	Telephone:  (212) 588-0022
	 	Email:  wsr@orllp.legal
	
         

         
	 
	If to the Holder:	YA II PN, Ltd.
	 	
        c/o Yorkville Advisors Global, LLC

        1012 Springfield Avenue

	 	Mountainside, NJ 07092
	 	Attention: Mark Angelo
	 	Telephone: 201-985-8300
	 	Email:  Legal@yorkvilleadvisors.com

 

or at such other
address and/or email and/or to the attention of such other person as the recipient party has specified by written notice
given to each other party three (3) Business Days prior to the effectiveness of such change. Written confirmation of receipt
(i) given by the recipient of such notice, consent, waiver or other communication, (ii) electronically generated by the
sender's email service provider containing the time, date, recipient email address or (iii) provided by a nationally
recognized overnight delivery service, shall be rebuttable evidence of personal service, receipt by facsimile or receipt from
a nationally recognized overnight delivery service in accordance with clause (i), (ii) or (iii) above, respectively.

 

    10

     

    

 

(7)              
Except as expressly provided herein, no provision of this Debenture shall alter or impair the obligations of the Company,
which are absolute and unconditional, to pay the Principal of, interest and other charges (if any) on, this Debenture at the time,
place, and rate, and in the coin or currency, herein prescribed. This Debenture is a direct obligation of the Company. As long
as this Debenture is outstanding, the Company shall not and shall cause their subsidiaries not to, without the consent of the Holder,
(i) amend its certificate of incorporation, bylaws or other charter documents so as to adversely affect any rights of the Holder;
(ii) repay, repurchase or offer to repay, repurchase or otherwise acquire shares of its Common Stock or other equity securities;
or (iii) enter into any agreement with respect to any of the foregoing.

 

(8)              
This Debenture shall not entitle the Holder to any of the rights of a stockholder of the Company, including without limitation,
the right to vote, to receive dividends and other distributions, or to receive any notice of, or to attend, meetings of stockholders
or any other proceedings of the Company, unless and to the extent converted into shares of Common Stock in accordance with the
terms hereof.

 

(9)              
No indebtedness of the Company is senior to this Debenture in right of payment, whether with respect to interest, damages
or upon liquidation or dissolution or otherwise. Without the Holder’s consent, the Company will not and will not permit any
of their subsidiaries to, directly or indirectly, enter into, create, incur, assume or suffer to exist any indebtedness of any
kind, on or with respect to any of its property or assets now owned or hereafter acquired or any interest therein or any income
or profits there from that is senior in any respect to the obligations of the Company under this Debenture.

 

(10)            
This Debenture shall be governed by and construed in accordance with the laws of the State of New Jersey, without giving
effect to conflicts of laws thereof. Each of the parties consents to the jurisdiction of the Superior Courts of the State of New
Jersey sitting in Hudson County, New Jersey and the U.S. District Court for the District of New Jersey sitting in Newark,
New Jersey in connection with any dispute arising under this Debenture and hereby waives, to the maximum extent permitted by law,
any objection, including any objection based on forum non conveniens to the bringing of any such proceeding in such jurisdictions.

 

(11)            
If the Company fails to strictly comply with the terms of this Debenture, then the Company shall reimburse the Holder promptly
for all fees, costs and expenses, including, without limitation, attorneys’ fees and expenses incurred by the Holder in any
action in connection with this Debenture, including, without limitation, those incurred: (i) during any workout, attempted workout,
and/or in connection with the rendering of legal advice as to the Holder’s rights, remedies and obligations, (ii) collecting
any sums which become due to the Holder, (iii) defending or prosecuting any proceeding or any counterclaim to any proceeding or
appeal; or (iv) the protection, preservation or enforcement of any rights or remedies of the Holder.

 

    11

     

    

 

(12)            
Any waiver by the Holder of a breach of any provision of this Debenture shall not operate as or be construed to be a waiver
of any other breach of such provision or of any breach of any other provision of this Debenture. The failure of the Holder to insist
upon strict adherence to any term of this Debenture on one or more occasions shall not be considered a waiver or deprive that party
of the right thereafter to insist upon strict adherence to that term or any other term of this Debenture. Any waiver must be in
writing.

 

(13)            
If any provision of this Debenture is invalid, illegal or unenforceable, the balance of this Debenture shall remain in effect,
and if any provision is inapplicable to any person or circumstance, it shall nevertheless remain applicable to all other persons
and circumstances. If it shall be found that any interest or other amount deemed interest due hereunder shall violate applicable
laws governing usury, the applicable rate of interest due hereunder shall automatically be lowered to equal the maximum permitted
rate of interest. The Company covenants (to the extent that it may lawfully do so) that it shall not at any time insist upon, plead,
or in any manner whatsoever claim or take the benefit or advantage of, any stay, extension or usury law or other law which would
prohibit or forgive the Company from paying all or any portion of the Principal of or interest on this Debenture as contemplated
herein, wherever enacted, now or at any time hereafter in force, or which may affect the covenants or the performance of this indenture,
and the Company (to the extent it may lawfully do so) hereby expressly waives all benefits or advantage of any such law, and covenants
that it will not, by resort to any such law, hinder, delay or impeded the execution of any power herein granted to the Holder,
but will suffer and permit the execution of every such as though no such law has been enacted.

 

(14)            
Whenever any payment or other obligation hereunder shall be due on a day other than a Business Day, such payment shall be
made on the next succeeding Business Day.

 

(15)           
THE PARTIES HEREBY KNOWINGLY, VOLUNTARILY AND INTENTIONALLY WAIVE THE RIGHT ANY OF THEM MAY HAVE TO A TRIAL BY JURY IN RESPECT
OF ANY LITIGATION BASED HEREON OR ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS AGREEMENT OR ANY TRANSACTION DOCUMENT OR ANY
COURSE OF CONDUCT, COURSE OF DEALING, STATEMENTS (WHETHER VERBAL OR WRITTEN) OR ACTIONS OF ANY PARTY. THIS PROVISION IS A MATERIAL
INDUCEMENT FOR THE PARTIES’ ACCEPTANCE OF THIS AGREEMENT.

 

(16)            
CERTAIN DEFINITIONS For purposes of this Debenture, the following terms shall have the following meanings:

 

(a)               
“Approved Stock Plan” means a stock option plan that has been approved by the Board of Directors of the
Company, pursuant to which the Company’s securities may be issued only to any employee, officer, or director for services
provided to the Company.

 

(b)               
"Bloomberg" means Bloomberg Financial Markets.

 

(c)               
“Business Day” means any day except Saturday, Sunday and any day which shall be a federal legal holiday
in the United States or a day on which banking institutions are authorized or required by law or other government action to close.

 

    12

     

    

 

(d)               
“Change of Control Transaction” means the occurrence of (a) an acquisition after the date hereof by an
individual or legal entity or “group” (as described in Rule 13d-5(b)(1) promulgated under the Exchange Act) of effective
control (whether through legal or beneficial ownership of capital stock of the Company, by contract or otherwise) of in excess
of fifty percent (50%) of the voting securities of the Company (except that the acquisition of voting securities by the Holder
or any other current holder of convertible securities of the Company shall not constitute a Change of Control Transaction for purposes
hereof), (b) a replacement at one time or over time of more than one-half of the members of the board of directors of the Company
(other than as due to the death or disability of a member of the board of directors) which is not approved by a majority of those
individuals who are members of the board of directors on the date hereof (or by those individuals who are serving as members of
the board of directors on any date whose nomination to the board of directors was approved by a majority of the members of the
board of directors who are members on the date hereof), (c) the merger, consolidation or sale of fifty percent (50%) or more of
the assets of the Company or any subsidiary of the Company in one or a series of related transactions with or into another entity,
or (d) the execution by the Company of an agreement to which the Company is a party or by which it is bound, providing for any
of the events set forth above in (a), (b) or (c). No transfer to a wholly-owned subsidiary shall be deemed a Change of Control
Transaction under this provision.

 

(e)                
“Closing Bid Price” means the price per share in the last reported trade of the Common Stock on a Primary
Market or on the exchange which the Common Stock is then listed as quoted by Bloomberg.

 

(f)                
“Convertible Securities” means any stock or securities (other than Options) directly or indirectly convertible
into or exercisable or exchangeable for Common Stock.

 

(g)               
“Commission” means the Securities and Exchange Commission.

 

(h)               
“Common Stock” means the common stock, par value $0.001, of the Company and stock of any other class
into which such shares may hereafter be changed or reclassified.

 

(i)                
 “Exchange Act” means the Securities Exchange Act of 1934, as amended.

 

(j)                 
“Floor Price” means $2.00 per share.

 

(k)               
“Fundamental Transaction” means any of the following: (1) the Company effects any merger or consolidation
of the Company with or into another Person and the Company is the non-surviving company (other than a merger or consolidation with
a wholly owned subsidiary of the Company for the purpose of redomiciling the Company), (2) the Company effects any sale of all
or substantially all of its assets in one or a series of related transactions, (3) any tender offer or exchange offer (whether
by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to tender or exchange their
shares for other securities, cash or property, or (4) the Company effects any reclassification of the Common Stock or any compulsory
share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property.

 

    13

     

    

 

(l)                
“Options” means any rights, warrants or options to subscribe for or purchase shares of Common Stock or
Convertible Securities

 

(m)              
“Other Debentures” means any other debentures issued pursuant to the Securities Purchase Agreement and
any other debentures, notes, or other instruments issued in exchange, replacement, or modification of the foregoing.

 

(n)               
“Original Issue Date” means the date of the first issuance of this Debenture regardless of the number
of transfers and regardless of the number of instruments, which may be issued to evidence such Debenture.

 

(o)               
“Person” means a corporation, an association, a partnership, organization, a business, an individual,
a government or political subdivision thereof or a governmental agency.

 

(p)               
“Primary Market” means any of the New York Stock Exchange, the NYSE MKT, the Nasdaq Global Market, the
Nasdaq Global Select Market, or the OTC QB, and any successor to any of the foregoing markets or exchanges.

 

(q)               
“Redemption Premium” means 20% of the Principal amount being redeemed.

 

(r)                
 “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated
thereunder.

 

(s)               
“Trading Day” means a day on which the shares of Common Stock are quoted or traded on a Primary Market
on which the shares of Common Stock are then quoted or listed; provided, that in the event that the shares of Common Stock are
not listed or quoted, then Trading Day shall mean a Business Day.

 

(t)                
“Transaction Document(s)” shall mean this Debenture, along with the Securities Purchase Agreement, and
any other documents or agreements entered into in connection with the foregoing.

 

(u)               
“Underlying Shares” means the shares of Common Stock issuable upon conversion of this Debenture or as
payment of interest in accordance with the terms hereof.

 

(v)               
“Underlying Shares Registration Statement” means a registration statement covering among other things
the resale of the Underlying Shares and naming the Holder as a “selling stockholder” thereunder.

 

(w)               
"VWAP" means, for any security as of any date, the daily dollar volume-weighted average price for such
security on the Primary Market as reported by Bloomberg through its “Historical Prices – Px Table with Average Daily
Volume” functions, or, if no dollar volume-weighted average price is reported for such security by Bloomberg.

 

    14

     

    

 

[Signature Page Follows]

 

    15

     

    

 

IN WITNESS WHEREOF,
the Company has caused this Convertible Debenture to be duly executed by a duly authorized officer as of the date set forth above.

 

	 	COMPANY:
	 	Q BIOMED INC.
	 	
        

         

	 	By:	           
	 	Name:
	 	Title:

 

    

     

    

 

EXHIBIT I

CONVERSION NOTICE

 

(To be executed by the Holder in order
to Convert the Debenture)

 

TO: Q BIOMED INC.

 

Via Email: dcorin@qbiomed.com; wsr@orllp.legal

 

The undersigned hereby
irrevocably elects to convert a portion of the outstanding and unpaid Conversion Amount of Debenture No. QBIO-[7] into Shares
of Common Stock of Q BIOMED INC., according to the conditions stated therein, as of the Conversion Date written below.

 

Conversion Date:

 

Principal Amount to be Converted:  

 

Accrued Interest to be Converted:  

 

Total Conversion Amount to be converted:  

 

Fixed Conversion Price:   

 

Variable Conversion Price:  

 

Applicable Conversion Price: 

 

Number of shares of Common Stock to be issued:

   

Please issue the shares of Common Stock in the following name and to the following address:

 

Issue to:

   

	Authorized
    Signature:	 
	Name:	 
	Title:	 
	Broker
    DTC Participant Code:	 
	Account
    Number:Exhibit

January 30, 2019

Mr. Mark Livingston
6702 Woodbend Park N. 
Houston, TX 77055

Dear Mark,

We are pleased to offer you the position of Controller with Quanex Building Products Corporation (“Company”), effective February 4, 2019, (“Effective Date”) reporting directly to me. 

The offer is contingent upon passing a pre-employment drug test and a satisfactory background check (employment, criminal and credit). The pre-employment drug test must be completed by you within 3 business days of the acceptance date of this offer.

Below is a summary of your compensation and benefits you will receive in connection with your employment with the Company: 
		
	1.
	Base Salary.  Your annual base salary will be $225,000, less applicable withholdings. It will be paid biweekly at a rate of $8,653.85, less applicable withholdings.

		
	2.
	Management Incentive Program.  You will be eligible to participate in the Quanex Building Products Management Incentive Program (MIP).  Payments are made per the MIP policy.  The award amounts are based upon your eligible wages and the Company’s financial/operational results for the fiscal year.  The current MIP target award level for your position is 50% of your base salary with a max of 100%, and subject to periodic review. 

		
	3.
	Initial Restricted Stock Grant.  You will receive 4,500 shares of Restricted Stock on the Effective Date of your employment.  This stock will cliff vest on December 4, 2021.  However in the event of a change in control, as defined in the 2008 Quanex Building Products Omnibus Incentive Plan, you will become fully vested in your restricted stock award. 

		
	4.
	Long Term Incentive Awards.  You will also be eligible to receive an annual Long Term Incentive Award based upon approval of the Compensation and Management Development Committee typically at the Company’s Q4 Board meeting.  The current target award level for your position is $70,000 in restricted stock (3 year cliff vest), subject to periodic review by the Compensation and Management Development Committee.  

		
	5.
	Vacation.  You will receive four weeks of vacation, which will be prorated based on your start date for the remainder of 2019, and the full 4 week allowance starts in calendar year 2020. Vacation is to be used in accordance with the Company’s Vacation Policy. 

		
	6.
	Benefits.  You will be eligible to participate in the Quanex Building Products Group Benefits Plan beginning on the first day of the month following 30 days of employment.  It is a flexible cafeteria plan that offers a variety of benefit choices from which you can select that will best meet the needs of you and your family.  Additionally, the Company provides certain benefits that are employer-paid (i.e. short-term disability, long-term disability, basic life insurance, and AD&D benefits).

		
	7.
	401(k) Plan.  You will be eligible to participate in the Quanex Building Products Salaried and Nonunion Employee 401(k) Plan beginning the first day of employment.  You may contribute up to a maximum of 50% of your eligible compensation up to the government mandated maximum.  Currently, Quanex will match $0.50 for each dollar you contribute up to a maximum of 5% of your eligible compensation.  There is a five year vesting schedule on the Company match.  In addition, you may elect to save on a before-tax or after-tax basis, or a combination of the two. 

		
	8.
	Pension.  You will be eligible for pension benefits under the Quanex Building Products Salaried and Nonunion Employee Pension Plan, (the “Pension Plan”) provided you meet the vesting requirements of the Plan.  The Pension plan consists of a notional account balance in your name.  Currently, the account will receive annual benefit credit of 4% based on your base pay plus bonus paid during the year, in addition to annual interest credits based on the 30 year Treasury (rate is established each August for the next year).  The benefit is portable once you are vested (100% after three years of vesting service), you can take it with you if you leave Quanex. 

		
	9.
	Executive Severance Provision. The purpose of this provision is to establish a severance provision for you that recognizes the relatively more difficult employment transition that occurs upon the termination of employment of higher paid individuals. Therefore, in the event that your employment is terminated by the Company during your first two years of employment for a reason other than for cause or material violation of the Company’s Code of Business Conduct & Ethics, you shall be entitled to the following benefits:

		
	a.
	Base Salary for One Year.  Annualized base salary as in effect immediately before the date of termination of employment, paid bi-weekly for a period of 12 months starting on the date of termination of employment.

		
	b.
	Continuation of Welfare Benefits.  The Company, at its expense, will pay COBRA (Consolidated Omnibus Reconciliation Act) premiums for the Company’s group health plan coverage (i.e. medical, dental, vision, life, disability and any other company welfare plans in which you participate) for up to 12 months following the termination of your employment. However, if during the 12 month period you become gainfully employed, the COBRA benefits shall cease and be terminated. 

In the event your termination is for cause or for a material violation of the Company’s Code of Business Conduct and Ethics, you will not be entitled to the severance terms as set forth above.
In the event your termination occurs after your second anniversary with the Company, you will receive the then-standard severance provision of the Company.
Notwithstanding any provision herein to the contrary, payment or provision of your benefits under this paragraph shall commence provided that you have delivered to the Company an executed and irrevocable full and complete Release of Claims against the Company, its affiliates, officers and directors in such form as is satisfactory to the Company (“Release of Claims”).  You shall forfeit any and all of the payments, reimbursement and benefits payable under this agreement if you do not provide the Company a Release of Claims.    
		
	10.
	Principal Office. The Quanex Building Products Corporation offices located at 1800 West Loop South, Suite 1500 in Houston, TX will be your principal reporting office. 

Your entitlement to any of the benefits outlined herein is contingent on your continued employment at the time. The above benefit(s) and/or compensation information is subject to change without notice per the terms, policies and/or practices of the Company.  

Your acceptance below is acknowledgment and agreement on your part to the offer of employment by the Company. Your acceptance of this offer does not modify the at-will employment relationship you enjoy with the Company, meaning either you or the Company may terminate the employment relationship at any time, with or without notice.  

Please sign your acceptance in the space below and return it to me no later than 
Thursday, January 31, 2019.

Feel free to call me at any time.

Sincerely,

/s/ Brent Korb

Brent Korb

ACCEPTANCE OF OFFER

/s/ Mark Livingston                     January 31, 2019
___________________________________        ________________________
Mark Livingston                        Date

www.quanex.com

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00302-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00302-of-00352.parquet"}]]